HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brown, J. R. Search for Related Content PubMed PubMed Citation Articles by Brown, J. R. Related Collections Cardiac - pharmacology Related Article

---

Original Articles: Adult Cardiac

Invited Commentary

The Dartmouth Institute for Health Policy and Clinical Practice, One Medical Center Drive, Lebanon, NH 03756

(Email: jbrown@dartmouth.edu).

The first 20% of the full text of this article appears below.

Ngaage and colleagues [1] investigated a single center 9-year experience with aprotinin (Trasylol; Bayer Pharmaceuticals Corp, West Haven, CT) among patients undergoing primary coronary artery bypass or valve surgery, or both. The premise of this study was to provide a uniform, single-center analysis on aprotinin in contrast with the lack of uniformity in the multicenter approaches. Propensity score matching was used to balance a subgroup of patients receiving or not receiving the full-dose aprotinin regimen. Primary outcomes of the analysis were 30-day mortality, ST segment elevated myocardial infarction, neurologic dysfunction (ie, confusion or cognitive decline), and renal insufficiency (ie, a serum creatinine > 200 µm/L or > 2.3 mg/dL). Secondary outcomes included total . . . [Full Text of this Article]

Related Article

Aprotinin in Primary Cardiac Surgery: Operative Outcome of Propensity Score-Matched Study

Dumbor L. Ngaage, Alexander R. Cale, Michael E. Cowen, Steven Griffin, and Levant Guvendik
Ann. Thorac. Surg. 2008 86: 1195-1202. [Abstract] [Full Text] [PDF]